Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

NCT06993506 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

500

Enrollment

OTHER

Sponsor class

Conditions

HER2-negative Breast Cancer
Recurrence
Metastasis

Interventions

DRUG: SKB264 Monotherapy or Combination Therapy

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences